drugset / Trial / NCT04544319

Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg

NCT04544319

Phase 1 Unknown 44 enrolled LG Chem
RandomizedCrossoverOpen-labelOther

Summary

To identify bioequivalence between Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg to Each Component of Gemigliptin 50 mg and Dapagliflozin 10 mg

Timeline

Start
2020-10
Primary completion
2021-03
Completion
2021-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg
Subject Gemigliptin Small molecule 50 mg
Subject Gemigliptin/Dapagliflozin Unknown